Literature DB >> 26727971

Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation.

Troy A McEachron1,2, Ivan Kirov3, Minkkwan Wungwattana4, Daisy Cortes5, Keri B Zabokrtsky2,6, Aaron Sassoon7, David Craig8, John D Carpten1, Leonard S Sender2,3,6,9.   

Abstract

Extranodal natural killer (NK)/T-cell lymphoma (ENKTCL) is a distinct type of non-Hodgkin lymphoma predominantly observed in Asian and Latin American adult males. A 12-year-old Hispanic female diagnosed with ENKTCL was enrolled in our genomic profiling research protocol. We identified specific somatic alterations consistent with diagnosis of ENKTCL as well as oncogenic mutations in MAP2K1 and STAT3. To our knowledge, this is the first report of an immunophenotypically confirmed and genetically profiled case of ENKTCL in a female pediatric patient in the United States, including its unique treatment and favorable outcome.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  STAT3; extranodal NK/T-cell lymphoma; genome

Mesh:

Substances:

Year:  2016        PMID: 26727971      PMCID: PMC7510171          DOI: 10.1002/pbc.25854

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  20 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  New prognostic model for extranodal natural killer/T cell lymphoma, nasal type.

Authors:  Qingqing Cai; Xiaolin Luo; Guanrong Zhang; Huiqiang Huang; Hui Huang; Tongyu Lin; Wenqi Jiang; Zhongjun Xia; Ken H Young
Journal:  Ann Hematol       Date:  2014-04-30       Impact factor: 3.673

3.  Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.

Authors:  Jeeyun Lee; Cheolwon Suh; Yeon Hee Park; Young H Ko; Soo Mee Bang; Jae Hoon Lee; Dae Ho Lee; Jooryung Huh; Sung Yong Oh; Hyuk-Chan Kwon; Hyo Jin Kim; Soon Il Lee; Jung Han Kim; Jinny Park; Seok Joong Oh; Kihyun Kim; Chulwon Jung; Keunchil Park; Won Seog Kim
Journal:  J Clin Oncol       Date:  2005-12-27       Impact factor: 44.544

4.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Authors:  Motoko Yamaguchi; Yok-Lam Kwong; Won Seog Kim; Yoshinobu Maeda; Chizuko Hashimoto; Cheolwon Suh; Koji Izutsu; Fumihiro Ishida; Yasushi Isobe; Eisaburo Sueoka; Junji Suzumiya; Takao Kodama; Hiroshi Kimura; Rie Hyo; Shigeo Nakamura; Kazuo Oshimi; Ritsuro Suzuki
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

5.  Oncogenic MAP2K1 mutations in human epithelial tumors.

Authors:  Young Lim Choi; Manabu Soda; Toshihide Ueno; Toru Hamada; Hidenori Haruta; Azusa Yamato; Kazutaka Fukumura; Mizuo Ando; Masahito Kawazu; Yoshihiro Yamashita; Hiroyuki Mano
Journal:  Carcinogenesis       Date:  2012-02-10       Impact factor: 4.944

Review 6.  Molecular underpinning of extranodal NK/T-cell lymphoma.

Authors:  Yenlin Huang; Laurence de Leval; Philippe Gaulard
Journal:  Best Pract Res Clin Haematol       Date:  2013-05-23       Impact factor: 3.020

7.  Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.

Authors:  Shen-meng Gao; Chi-qi Chen; Lu-yao Wang; Li-li Hong; Jian-bo Wu; Pei-hong Dong; Fu-jun Yu
Journal:  Exp Hematol       Date:  2012-10-27       Impact factor: 3.084

8.  Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.

Authors:  Motoko Yamaguchi; Kensei Tobinai; Masahiko Oguchi; Naoki Ishizuka; Yukio Kobayashi; Yasushi Isobe; Kenichi Ishizawa; Nobuo Maseki; Kuniaki Itoh; Noriko Usui; Izumi Wasada; Tomohiro Kinoshita; Koichi Ohshima; Yoshihiro Matsuno; Takashi Terauchi; Shigeru Nawano; Satoshi Ishikura; Yoshikazu Kagami; Tomomitsu Hotta; Kazuo Oshimi
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

9.  STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.

Authors:  Andres Jerez; Michael J Clemente; Hideki Makishima; Hanna Koskela; Francis Leblanc; Kwok Peng Ng; Thomas Olson; Bartlomiej Przychodzen; Manuel Afable; Ines Gomez-Segui; Kathryn Guinta; Lisa Durkin; Eric D Hsi; Kathy McGraw; Dan Zhang; Marcin W Wlodarski; Kimmo Porkka; Mikkael A Sekeres; Alan List; Satu Mustjoki; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

10.  Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.

Authors:  N K El-Mallawany; J K Frazer; P Van Vlierberghe; A A Ferrando; S Perkins; M Lim; Y Chu; M S Cairo
Journal:  Blood Cancer J       Date:  2012-04-13       Impact factor: 11.037

View more
  2 in total

Review 1.  Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions.

Authors:  John C Reneau; Polina Shindiapina; Zachary Braunstein; Youssef Youssef; Miguel Ruiz; Saira Farid; Walter Hanel; Jonathan E Brammer
Journal:  J Clin Med       Date:  2022-05-10       Impact factor: 4.964

Review 2.  Extranodal NK/T cell lymphoma.

Authors:  Seong Hyun Jeong
Journal:  Blood Res       Date:  2020-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.